UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 251

Sortiert nach

Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2008-04, Vol.51 (16), p.1527-1538

2008

Volltextzugriff (PDF)

Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2008-10, Vol.178 (7), p.729-737

2008

Volltextzugriff (PDF)

Left atrial structure and function and clinical outcomes in the general population

European heart journal, 2013-01, Vol.34 (4), p.278-285

2013

Volltextzugriff (PDF)

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study

The Journal of heart and lung transplantation, 2019-01, Vol.38 (1), p.43-50

2019

Volltextzugriff (PDF)

Characterizing the Right Ventricle: Advancing Our Knowledge

The American journal of cardiology, 2012-09, Vol.110 (6), p.S3-S8

2012

Volltextzugriff (PDF)

The right ventricle in pulmonary hypertension

Coronary artery disease, 2005-02, Vol.16 (1), p.13-18

2005

Volltextzugriff (PDF)

Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving?

Circulation (New York, N.Y.), 2023-02, Vol.147 (7), p.562-564

2023

Volltextzugriff (PDF)

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Pulmonary therapy, 2024-03, Vol.10 (1), p.85-107

2024

Volltextzugriff (PDF)

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study

The American heart journal, 2014-02, Vol.167 (2), p.218-225.e1

2014

Volltextzugriff (PDF)

Right Heart Adaptation to Pulmonary Arterial Hypertension: Physiology and Pathobiology

Journal of the American College of Cardiology, 2013-12, Vol.62 (25), p.D22-D33

2013

Volltextzugriff (PDF)

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2021-10, Vol.78 (14), p.1393-1403

2021

Volltextzugriff (PDF)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

ERJ open research, 2023-01, Vol.9 (1), p.456-2022

2023

Volltextzugriff (PDF)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Pulmonary circulation, 2023-04, Vol.13 (2), p.e12226-n/a

2023

Volltextzugriff (PDF)

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Pulmonary circulation, 2022-10, Vol.12 (4), p.e12150-n/a

2022

Volltextzugriff (PDF)

Reply: Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?

Journal of the American College of Cardiology, 2022-02, Vol.79 (7), p.e177-e177

2022

Volltextzugriff (PDF)

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2024-01, Vol.83 (4), p.473-484

2024

Volltextzugriff (PDF)

Lessons from the COMPASS-3 Study

Pulmonary circulation, 2018-01, Vol.8 (1), p.1-3

2018

Volltextzugriff (PDF)

Association of Cardiac Troponin I With Disease Severity and Outcomes in Patients With Pulmonary Hypertension

The American journal of cardiology, 2013-06, Vol.111 (12), p.1812-1817

2013

Volltextzugriff (PDF)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Circulation (New York, N.Y.), 2019-05, Vol.139 (21), p.2440-2450

2019

Volltextzugriff (PDF)

Changes in Right Ventricular Structure and Function Assessed Using Cardiac Magnetic Resonance Imaging in Bosentan -Treated Patients With Pulmonary Arterial Hypertension

The American journal of cardiology, 2008-06, Vol.101 (11), p.1669-1672

2008

Volltextzugriff (PDF)

Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis

Circulation. Heart failure, 2015-11, Vol.8 (6), p.1032-1043

2015

Volltextzugriff (PDF)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

European journal of heart failure, 2022-01, Vol.24 (1), p.205-214

2022

Volltextzugriff (PDF)

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Chest, 2021-07, Vol.160 (1), p.277-286

2021

Volltextzugriff (PDF)

Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids

Chest, 2018-09, Vol.154 (3), p.532-540

2018

Volltextzugriff (PDF)

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study

The Journal of heart and lung transplantation, 2020-04, Vol.39 (4), p.300-309

2020

Volltextzugriff (PDF)

1 – 25 von 251

Suche als RSS-Feed

Aktive Filter

ThemaPulmonary Hypertension

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(233)
Mit Volltextzugriff
(228)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Pulmonary Arterial Hypertension

Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis

Left atrial structure and function and clinical outcomes in the general population

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study

Characterizing the Right Ventricle: Advancing Our Knowledge

The right ventricle in pulmonary hypertension

Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving?

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study

Right Heart Adaptation to Pulmonary Arterial Hypertension: Physiology and Pathobiology

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Reply: Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Lessons from the COMPASS-3 Study

Association of Cardiac Troponin I With Disease Severity and Outcomes in Patients With Pulmonary Hypertension

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Changes in Right Ventricular Structure and Function Assessed Using Cardiac Magnetic Resonance Imaging in Bosentan -Treated Patients With Pulmonary Arterial Hypertension

Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study

Aktive Filter

Suchergebnisse filtern